KlockLE, MillerTD, MorrisAH, WatanabeS, DickmanM.A comparative study of atropine sulfate and isoproterenol hydrochloride in chronic bronchitis. Am Rev Respir Dis1975;112:371–376.
GrossNJ. Sch 1000: A new anticholinergic bronchodilator. Am Rev Respir Dis1975;112:823–828.
10.
SpectorS, BallREJr. Bronchodilating effects of aerosolized Sch 1000 and atropine sulfate in asthmatics (abstract). Chest1975;68:426.
11.
BandouvakisJ, CartierA, RobertsR, RyanG, HargreaveFE. The effect of ipratropium and fenoterol on methacholine- and histamine-induced bronchoconstriction. Br J Dis Chest1981; 75:295–305.
12.
PakesGE, BrogdenRN, HeelRC, SpeightTM, AveryGS. Ipratropium bromide: A review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis. Drugs1980;20:237–266.
13.
WolkoveN, KreismanH, FrankH, GentM.The effect of ipratropium on exercise-induced bronchoconstriction. Ann Allergy1981;47:311–315.
14.
RuffinRE, WolffRK, DolovichDB, RossmanCM, FitzgeraldJD, NewhouseMT. Aerosol therapy with Sch 1000. Short term mucociliary clearance in normal and bronchitic subjects and toxicology in normal subjects. Chest1978;73:501–506.
15.
RichardsonPS, PhippsRJ. The anatomy, physiology, pharmacology and pathology of tracheobronchial mucus secretion and the use of expectorant drugs in human disease. Pharmacol Ther B1978;3:441–479.
16.
FrancisRA, ThomsonML, PaviaD, DouglasRB. Ipratropium bromide: Mucociliary clearance rate and airway resistance in normal subjects. Br J Dis Chest1977;71:173–178.
17.
PuchelleE, UffholtzH.Sputum viscoelasticity following administration of Sch 1000 MDI (abstract 4/7). Postgrad Med J1975;51(Suppl 7):109.
18.
ColemanAJ, LearyUP, KaulDS. Haemodynamic effects of Sch 1000 in normal subjects (abstract 6/1). Postgrad Med J1975;51(Suppl 7):121.
19.
AdlungJ, GohleKD, ZerenS, WahlD.Studies of pharmacokinetics and biotransformation of ipratropium in man. Arzneim Forsch1976;26:1005–1010.
20.
KalserSC, McLainPL. Atropine metabolism in man. Clin Pharmacol Ther1970;11:214–227.
21.
ThiessenB, PedersenOF. Maximal expiratory flows and forced vital capacity in normal, asthmatic, and bronchitic subjects after salbutamol and ipratropium bromide. Respiration1982;43:304–316.
22.
MannNP, HillerEJ. Ipratropium bromide in children with asthma. Thorax1982;37:72–74.
23.
KreismanH, FrankH, WolkoveN, GentM.Anticholinergic therapy in bronchial asthma: Synergistic effect of ipratropium and theophylline (abstract). Am Rev Respir Dis1978; 117(Part 2):142.
24.
RasmussenFV, MadsenL, BundgaardA.Combined effect of an anticholinergic drug, ipratropium bromide, and disodium cromoglycate in exercise-induced asthma. Scand J Respir Dis [Suppl] 1979;103:159–162.
25.
AjewskiZ, PopiakB.The relation between permanent administration of Atrovent and the dose of steroid in chronic bronchitis (abstract). Scand J Respir Dis [Suppl] 1979;103:205.
ElwoodRK, AbboudRT. The short-term bronchodilator effects of fenoterol and ipratropium in asthma. J Allergy Clin Immunol1982;69:467–473.
28.
NolteD.Double-blind crossover comparison between a beta-adrenergic agent and a new anticholinergic agent by metered dose inhaler. Respiration1978;36:32–38.
29.
FlohrE, BischoffKO. Oxitropium bromide, a new anticholinergic drug, in a dose-response and placebo comparison in obstructive airway disease. Respiration1979;38:98–104.
30.
Schultze-WerninghausG.Anticholinergic versus beta 2-adrenergic therapy in allergic airways obstruction. Respiration1981;41:239–247.
31.
LarssonK.Oxitropium bromide, ipratropium bromide and fenoterol in exercise-induced asthma. Respiration1982;43:57–63.
